An Exploratory, Randomized, Double-blind, Parallel-group, Multicenter Study to Compare Secukinumab 300 mg With Placebo After 16 Weeks of Treatment in Adults With Moderate to Severe Plaque Psoriasis and Subclinical Enthesitis Measured by Musculoskeletal Ultrasound
Latest Information Update: 02 Dec 2021
At a glance
- Drugs Secukinumab (Primary)
- Indications Plaque psoriasis; Psoriatic arthritis
- Focus Therapeutic Use
- Acronyms INTERCEPT
- Sponsors Novartis Pharmaceuticals
- 30 Nov 2021 Planned End Date changed from 7 Apr 2022 to 24 Mar 2021.
- 30 Nov 2021 Planned primary completion date changed from 17 Feb 2022 to 24 Mar 2021.
- 29 Oct 2021 Status changed from recruiting to withdrawn prior to enrolment.